Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab: a retrospective, multicentre study
No Thumbnail Available
Authors
Dhanapal, Vijay
Gunasekara, Menaka
Lianwea, Chia
Marcus, Robert
De Lord, Corinne
Bowcock, Stella
Devereux, Stephen
Patten, Piers
Yallop, Deborah
Wrench, David
Contact
Check for full-text access
Issue Date
2017
Type
Article
Language
Keywords
Alternative Title
Abstract
The treatment of relapsed aggressive lymphoma remains a challenge. Platinum-containing chemotherapy is standard of care. Gemcitabine/oxaliplatin (Gem-Ox) with or without rituximab (R) is an outpatient regimen with a favorable toxicity profile. This retrospective 'real world' study reports outcomes for 44 unselected patients with relapsed/refractory aggressive lymphoma treated with Gem-Ox ± R. 41% had primary refractory disease. The overall response rate (ORR) was 43% with a complete response (CR) of 30%. Response to the prior treatment regimen significantly affected the ORR with only 8% achieving CR if prior remission was <12 months. Grade 3-4 hematological toxicity was common and 22% had febrile neutropenia. Eight patients proceeded to stem cell transplant. Overall, outcomes remain poor with a median overall survival of 8 months. In this high-risk group of patients, Gem-Ox ± R results in similar responses to other more toxic, inpatient regimens and should therefore be considered as second line therapy in relapsed lymphoma.
Description
Citation
Publisher
License
Journal
Leukemia & Lymphoma
Volume
58
Issue
9